FDA Committee Unanimously Recommends New mRNA Flu Vaccine for Adults

The FDA's top vaccine committee just made a move that might surprise some, especially given the current political climate around mRNA tech. They unanimously recommended Moderna's mFlusiva, an mRNA flu vaccine specifically for adults 50 and older. This marks the committee's first new vaccine review since 2023, and it could be the first vaccine approved under the second Trump administration.

Yes, you read that right. Despite past criticisms of vaccines from President Trump and Health and Human Services Secretary Robert F. Kennedy Jr. (who famously pulled almost half a billion dollars in mRNA vaccine development contracts last year), the scientific consensus rolled on. As Dr. Paul Offit, a former committee member, put it: a "breath of fresh air."

A Speedy, Stronger Shot?

Initially, the FDA seemed to drag its feet, declining Moderna's application in February, only to reverse course two weeks later after some public head-scratching. Now, here we are.

So, what's the big deal with an mRNA flu shot? Much like the COVID-19 vaccines, this tech gives your body instructions to build immunity by creating flu antigens. Moderna's version targets three to four flu strains with tiny doses of mRNA. Experts are genuinely excited because it could offer stronger, more reliable protection. Plus, mRNA vaccines can be manufactured faster than traditional ones — a huge advantage if a new, nasty flu strain pops up out of nowhere.

Moderna and the FDA found no credible safety risks, with Moderna emphasizing that the vaccine "does not enter the cellular nucleus, does not interact with the genome… and does not persist in the body." Which, if you think about it, is a pretty solid selling point.

Research published in the New England Journal of Medicine and Nature Immunology backs this up. Scientists found the mRNA vaccine created a longer-lasting immune response and antibodies that recognized more flu strains. This suggests it could be more effective than your standard annual jab.

Dr. Anna Durbin, a VRBPAC member from Johns Hopkins, confirmed that the review followed standard FDA guidelines, including a "full efficacy evaluation" involving "tens of thousands of individuals." And just in case you were wondering, Dr. Jesse Goodman, former director of FDA's Center for Biologics Evaluation and Research, was quick to address the politicization, calling claims of mRNA vaccines causing cancer or altering DNA "not possible [and] disproven."

Over 6 billion doses of mRNA vaccines have been administered since 2020, with an "incredibly safe safety profile," Durbin noted. "The mRNA platform has really been a game changer for vaccines," she added. Hard to argue with those numbers.

The Vote and What Comes Next

After a six-and-a-half-hour meeting, all nine committee members voted to recommend the vaccine. CDC data shared during the meeting painted a stark picture of the 2025-2026 flu season: at least 32 million cases, 390,000 hospitalizations, and 24,000 deaths in the U.S. And a whopping 85% of those eligible weren't fully vaccinated. Clearly, there's room for improvement.

Evan Anderson, Moderna's vice president of epidemiology, highlighted another key benefit: the mRNA vaccine could cut the time it takes to target a specific flu strain from six months down to two or three. That's a serious speed boost for public health.

Dr. Gauri Raval, an FDA medical officer, concluded that the Moderna mRNA flu vaccine "may offer greater efficacy than the standard dose comparator in preventing more severe influenza-associated illness[es]." No major safety issues, no deficiencies. Just a unanimous thumbs-up.

While the FDA's initial hesitation to review the vaccine was unusual, the fact that the VRBPAC committee remained intact and conducted a robust, public discussion offers a glimmer of hope. Especially given concerns about the CDC's Advisory Committee on Immunization Practices (ACIP), which determines how vaccines are used, having seen some of its highly qualified members reportedly fired.

If the agencies under Kennedy's purview approve and recommend it, Moderna believes this new mRNA flu shot could be ready for the next flu season. Which, if you're over 50, might just be something to look forward to.